(89)Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: implications for future cancer therapy.

AIMS Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. MATERIALS & METHODS Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. RESULTS The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. CONCLUSION The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection.

[1]  Anne Bol,et al.  Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of 89Zr-labeled cetuximab in mice. , 2013, Contrast media & molecular imaging.

[2]  Bernard Gallez,et al.  Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vitro and in vivo study , 2012 .

[3]  David S Mendelson,et al.  A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[4]  Nikolai G. Khlebtsov,et al.  Gold Nanoparticles in Biomedical Applications: Recent Advances and Perspectives , 2012 .

[5]  G. Murdoch,et al.  Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer , 2011, mAbs.

[6]  D. Abou,et al.  In vivo biodistribution and accumulation of 89Zr in mice. , 2011, Nuclear medicine and biology.

[7]  S. Singh,et al.  Functionalized Gold Nanoparticles and Their Biomedical Applications , 2011, Nanomaterials.

[8]  G. V. van Dongen,et al.  (89)Zr-labeled compounds for PET imaging guided personalized therapy. , 2011, Drug discovery today. Technologies.

[9]  S. Curley,et al.  Non-Invasive Radiofrequency-Induced Targeted Hyperthermia for the Treatment of Hepatocellular Carcinoma , 2011, International journal of hepatology.

[10]  P. Carmeliet,et al.  Molecular mechanisms and clinical applications of angiogenesis , 2011, Nature.

[11]  O. Feron,et al.  Antibody immobilization on gold nanoparticles coated layer-by-layer with polyelectrolytes , 2011 .

[12]  Yin Zhang,et al.  Positron emission tomography imaging of CD105 expression during tumor angiogenesis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  B. Bryan,et al.  Anti‐angiogenic therapy: Adapting strategies to overcome resistant tumors , 2010, Journal of cellular biochemistry.

[14]  S. Curley,et al.  Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles. , 2010, Surgery.

[15]  S. Curley,et al.  Radiofrequency field‐induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles , 2010, Cancer.

[16]  L. Giacomelli,et al.  CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[17]  Cui Tang,et al.  Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. , 2010, Biomaterials.

[18]  Catherine J. Murphy,et al.  Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? , 2010, Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology.

[19]  Judith E. Flores,et al.  Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. , 2010, Nuclear medicine and biology.

[20]  M. Maio,et al.  Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. , 2010, Cardiovascular research.

[21]  P. Jurek,et al.  Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine , 2010, Nature Protocols.

[22]  A. Staffieri,et al.  Maspin expression in head and neck carcinoma: subcellular localization matters. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[23]  Jason S. Lewis,et al.  Standardized methods for the production of high specific-activity zirconium-89. , 2009, Nuclear medicine and biology.

[24]  G. V. van Dongen,et al.  p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  B. Seon,et al.  Anti‐endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature , 2009, International journal of cancer.

[26]  O. Feron,et al.  PVD Synthesis and Transfer into Water-Based Solutions of Functionalized Gold Nanoparticles , 2009 .

[27]  Carter Kittrell,et al.  Size-dependent joule heating of gold nanoparticles using capacitively coupled radiofrequency fields , 2009 .

[28]  G. Borthwick,et al.  Endoglin and activin receptor-like-kinase 1 are co-expressed in the distal vessels of the lung: implications for two familial vascular dysplasias, HHT and PAH , 2009, Laboratory Investigation.

[29]  M. Miyazaki,et al.  Specific Expression of Endoglin (CD105) in Endothelial Cells of Intratumoral Blood and Lymphatic Vessels in Pancreatic Cancer , 2008, Pancreas.

[30]  Yihai Cao,et al.  A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. , 2008, Cancer research.

[31]  A. Shiau,et al.  Increased apoptotic potential and dose‐enhancing effect of gold nanoparticles in combination with single‐dose clinical electron beams on tumor‐bearing mice , 2008, Cancer science.

[32]  B. Seon,et al.  Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice , 2008, International journal of cancer.

[33]  Xiulan Zhao,et al.  Pilot study on the interaction between B16 melanoma cell-line and bone-marrow derived mesenchymal stem cells. , 2008, Cancer letters.

[34]  Petra Krystek,et al.  Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. , 2008, Biomaterials.

[35]  G. V. van Dongen,et al.  Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.

[36]  H. Coenen,et al.  A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of 88Zr and 89Zr in proton induced reactions on yttrium , 2007 .

[37]  Stanislav Emelianov,et al.  Molecular specific optoacoustic imaging with plasmonic nanoparticles. , 2007, Optics express.

[38]  G. Soma,et al.  Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[39]  Marc C. Huisman,et al.  Performance evaluation of the Philips MOSAIC small animal PET scanner , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[40]  B. Seon,et al.  Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. , 2006, International journal of oncology.

[41]  M. Garnett,et al.  Nanomedicines and nanotoxicology: some physiological principles. , 2006, Occupational medicine.

[42]  P. Del Rio,et al.  The risk of developing metastatic disease in colorectal cancer is related to CD105‐positive vessel count , 2006, Journal of surgical oncology.

[43]  M. Hussein.  Transforming growth factor‐β and malignant melanoma: molecular mechanisms , 2005 .

[44]  B. Teicher,et al.  Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions , 2005 .

[45]  M. Hussein.  Transforming growth factor-beta and malignant melanoma: molecular mechanisms. , 2005, Journal of cutaneous pathology.

[46]  J. Hainfeld,et al.  The use of gold nanoparticles to enhance radiotherapy in mice. , 2004, Physics in medicine and biology.

[47]  P. Bonnier,et al.  Tumor Neoangiogenesis by CD31 and CD105 Expression Evaluation in Breast Carcinoma Tissue Microarrays , 2004, Clinical Cancer Research.

[48]  S. Kumar,et al.  Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis , 2003, British Journal of Cancer.

[49]  M. Botelho,et al.  Lymphatic Uptake of Pulmonary Delivered Radiolabelled Solid Lipid Nanoparticles , 2002, Journal of drug targeting.

[50]  H. Wada,et al.  Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  B. Seon,et al.  Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. , 2001, Cancer research.

[52]  M. Maio,et al.  Endoglin: An accessory component of the TGF‐β‐binding receptor‐complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies , 2001, Journal of cellular physiology.

[53]  M. Tabata,et al.  Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using 125I‐labeled anti‐endoglin monoclonal antibodies , 1999, International journal of cancer.

[54]  A. Ramaswamy,et al.  Elevated expression of endoglin, a component of the TGF‐β‐receptor complex, correlates with proliferation of tumor endothelial cells , 1999, International journal of cancer.

[55]  S. Kumar,et al.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. , 1999, Cancer research.

[56]  M. Barcos,et al.  Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  P. Lastres,et al.  Endoglin, a component of the TGF‐β receptor system, is a differentiation marker of human choriocarcinoma cells , 1998, International journal of cancer.

[58]  M. Barcos,et al.  Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  A. Gazdar,et al.  Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  S. Kumar,et al.  A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues , 1993, International journal of cancer.

[61]  D. Ruiter,et al.  A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. , 1993, The Journal of investigative dermatology.

[62]  B. Seon,et al.  Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Mealey.  Turn-over of Carrier-free Zirconium-89 in Man , 1957, Nature.